Ethicon Pelvic Mesh: What the Sales Pitch Left Out

Ethicon pelvic mesh enforcement cases included a $9.9 million Washington settlement over allegations that Johnson & Johnson omitted serious risks from product instructions and marketing. California imposed civil penalties, and a separate multistate agreement required changes to mesh promotion. For an insider in device sales, medical affairs or regulatory work, these cases follow a familiar trail: what the business knew about its product, what it told doctors and patients, and what supported the pitch.

Ethicon is a Johnson & Johnson subsidiary. Its pelvic mesh products included implants supporting pelvic organs and slings used to treat stress urinary incontinence. Washington described the devices as permanent polypropylene implants and alleged that the company omitted risks including chronic pain, pain during intercourse and urinary problems. The women receiving a permanent implant bore the consequences of the risks the state said the company had left out. Removing the mesh could be extremely difficult or impossible.

Does FDA-Cleared Mean the Same as FDA-Approved?

No. Clearance by the Food and Drug Administration through substantial equivalence compares a device with one already legally marketed. Premarket approval requires evidence giving reasonable assurance of safety and effectiveness for the intended use. A sales representative who substitutes approved for cleared changes what the customer is being told about the product’s review.

That distinction reached directly into the California case. The state identified statements in instructions for use and marketing communications that described Ethicon’s pelvic mesh as FDA approved even though the products had been cleared. The instructions traveled with the device and addressed the surgeon performing the operation. Their account of uses and adverse reactions belonged beside the brochure and sales presentation when assessing what the company communicated.

The regulatory history explains why the distinction mattered. Transvaginal mesh for pelvic organ prolapse had reached the market through substantial-equivalence clearances. On January 5, 2016, the Food and Drug Administration reclassified that device type into Class III, concluding that the existing controls were insufficient to provide reasonable assurance of safety and effectiveness. A companion order required premarket approval. That action concerned mesh placed through the vagina to repair prolapse, a specific use within the broader pelvic-mesh business.

California’s Written Materials Carried the Penalty

California won civil penalties over written materials that called Ethicon’s cleared pelvic mesh FDA approved and understated the scope and severity of mesh-specific risks.

Washington’s Settlement Reached the Risks and the Research

Washington’s April 22, 2019 resolution addressed alleged omissions in instructions for doctors and marketing for patients. The state’s lawsuit alleged that Johnson & Johnson knowingly left debilitating complications out of the instructions accompanying devices sold from 1999 to late 2015. It also alleged that the company downplayed serious complications in some product communications.

According to the attorney general’s announcement, Johnson & Johnson’s global head of medical affairs admitted in a deposition that the company knew about the serious risks from the beginning but did not inform patients. A warning inside a company and the warning inside a product box can tell very different stories.

The resolution required disclosure of newly learned significant risks and truthful, accurate, balanced promotional material. It also addressed a quieter part of the sales process: when Johnson & Johnson sponsored research and cited it in promotion, it had to disclose that sponsorship.

That condition connects the clinical paper to the commercial message. A reader weighing a study needs to know when the company selling the implant sponsored the evidence used to sell it. For medical affairs and marketing employees, the study, its funding and the way a sales aid cites it belong in the same account.

The Multistate Agreement Reached the Sales Force

In October 2019, 41 states and the District of Columbia entered consent judgments totaling $116,860,000. Their terms addressed the language of FDA authorization and the evidence behind clinical claims.

The judgments prohibited Ethicon from describing surgical mesh as FDA approved or as having undergone premarket approval unless that was true. They also required the company to train each representative on the accurate approval or clearance status of every surgical mesh product that person promoted or sold, before the promotion or sale.

The training had to cover each product. An employee responsible for a launch, training deck or field update would recognize the work involved: the product’s actual status had to reach the person delivering the sales message.

A separate provision reached the clinical and preclinical data cited in promotion. Ethicon could not cite data it had once held unless it still had or controlled that data. A favorable claim could not keep circulating after the company discarded the evidence behind it.

Together, these terms followed the pitch back into the business. The FDA-status statement had to match the product, the representative had to know that status, and the cited data had to remain available. Washington’s sponsorship condition added another question about the evidence: who paid for it?

What Device Insiders Can Explain

The commercial chain in these cases runs through the materials used to influence a clinical choice. Product instructions describe uses and risks. Patient brochures present the treatment. Sales representatives carry the message into the practice, while studies and clinical data support the claims being made.

Different employees can explain different parts of that chain. A regulatory employee may know how an authorization was described internally. A medical affairs employee may know the risk information behind a proposed warning. A sales employee may know which version of a presentation reached physicians and how the product was described in conversation.

The comparison is specific: a risk known internally against a risk disclosed externally, a product’s actual FDA status against the status claimed in promotion, or a study cited against the data the company retained. These are questions our whistleblower experts work through with the person who understands the business. California’s distinction between written materials and unproved oral communications shows why knowing the actual words can matter as much as knowing that a meeting happened.

From a Device Representation to a Government Payment

Ethicon’s state consumer resolutions concern what the company told doctors and patients. A federal False Claims Act case follows the connection to a false demand for government money.

The 2020 Journal of Forensic and Investigative Accounting paper A Forensic Accountant’s Guide to the Most Potent Federal Laws Used Against Healthcare Fraud explains that healthcare fraud can involve a false bill sent to an intermediary when federal funds supply the payment. The paper also examines whether a false statement caused a wrongful payment. For a device insider, that means looking beyond the sales pitch to the health care bill: what the hospital or physician asked Medicare to pay, and how the manufacturer’s statement affected that request.

CareFusion provides a related authorization example. In a separate qui tam case, the distributor agreed to a $3.3 million civil settlement and admitted buying and selling devices without the required FDA approval or clearance. The instruments had been represented as exempt based on their claimed marketing history. The company admitted that the manufacturer’s evidence for that claimed exemption was insufficient. The device’s status, the explanation used to sell it and what the distributor knew all belonged to the same transaction.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Our whistleblower experts turn what device insiders know into a case built on the sales, claims and decisions behind the product.

You Know What Reached the Doctor

If you know how a mesh risk, FDA-status claim or clinical finding changed on its way into a sales message, talk with our whistleblower experts about what you saw. We build your strongest case with medical device fraud whistleblower lawyers who understand device marketing, and stay beside you throughout the process.